Immucell Corp
$9.95
-$0.03 (-0.30%)
$9.68Day Range$9.99
Key Statistics
Market Cap
$90.64M
Shares Outstanding
9.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 8, 1987
Round Lot
100
Locale
US
Trading Data
Day Open
$9.80
Day High
$9.99
Day Low
$9.68
Volume
10.0K
VWAP
$9.83
Prev Close
$9.98
Transactions
--
Acc. Volume
--
About Immucell Corp
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 283573 employees56 EVERGREEN DR, PORTLAND, ME, 04103(207) 878-2770IPO Jul 8, 1987US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000811641
- Composite FIGI
- BBG000BLQ5Q2
- Share Class FIGI
- BBG001S5S3P1
- Ticker Root
- ICCC
- SIC Code
- 2835
About Immucell Corp (ICCC) Stock
Immucell Corp (ICCC) closed the 2026-09-18 session at $9.95, down 0.30% versus the previous close (-0.03). The stock opened at $9.80 and traded between $9.68 and $9.99 during that session. Session trading volume was 10K shares. The volume-weighted average price (VWAP) is $9.83.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Immucell Corp has a market capitalization of $90.6 million. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. ICCC is listed on the XNAS exchange. The company employs approximately 73 people. Immucell Corp is headquartered in PORTLAND, ME. The recorded listing date is 1987-07-08.
On this page you can find market ICCC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.